Fulcrum Therapeutics, Inc. FULC
3.74
(0.05)
(1.32%)
as of 25 Sep
- Market cap
- $288.8M
- P/E
- 0.0×
Follow FULC
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | — | — | 33.65 | 32.64 | 56.04 | 157.59 | 3.53 | — |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
— | — | — | (14.97) | (28.62) | (18.05) | (19.09) | (17.38) | — |
P/B ratio |
— | — | — | 3.12 | 2.96 | 1.79 | 1.88 | 1.20 | — |
Price to Tangible BV |
— | — | — | 3.12 | 2.96 | 1.79 | 1.88 | 1.20 | — |
EV/Sales |
— | — | — | 20.85 | 21.26 | 24.05 | 73.38 | 0.61 | — |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | — | (3.43) | (5.19) | (1.57) | (2.26) | (22.68) | — |
EV/FCF |
— | — | — | (3.35) | (5.08) | (1.54) | (2.25) | (20.15) | — |
Quick Ratio |
0.16 | 17.33 | 7.98 | 4.32 | 11.55 | 12.15 | 17.31 | 22.01 | 27.00 |
Current Ratio |
0.48 | 17.52 | 8.24 | 4.47 | 11.77 | 12.41 | 17.71 | 22.63 | 27.40 |
Net Debt/EBITDA |
0.02 | 2.26 | 1.18 | 1.63 | 2.78 | 1.84 | 2.18 | 11.87 | 4.23 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.07 | 0.11 | 0.03 | 0.01 | 0.31 | 0.00 |
Operating CF/Net income |
0.79 | 0.58 | 0.44 | 0.76 | 0.97 | 0.88 | 0.93 | 0.23 | 0.80 |
Capex/Depreciation |
(2.67) | (6.68) | (0.42) | (0.56) | (0.68) | (0.81) | (0.23) | (0.17) | (0.23) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 52.35% | 80.77% | (764.85%) | (77.68%) | (52.72%) | (53.53%) | (44.84%) | (4.07%) | (25.30%) | |
| (56.31%) | (86.89%) | (91.54%) | (59.01%) | (44.35%) | (47.60%) | (40.19%) | (3.75%) | (23.89%) | |
ROIC |
(1,570.56%) | (653.65%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (679.86%) | 0.00% |
Return on Tangible Assets |
(1,697.06%) | (48.68%) | (92.44%) | (69.99%) | (37.75%) | (55.57%) | (41.64%) | (4.01%) | (21.56%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 104.71 | 69.27 | 13.18 | 69.88 | 9.56 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 669.18% | 363.73% | 1,210.69% | 2,559.75% | 79.23% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 242.46% | 159.24% | 657.43% | 1,485.49% | 45.56% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 83.30% | 57.77% | 210.50% | 527.70% | 18.19% | 0.00% |
Graham Net Nets |
— | — | — | 0.29 | 0.32 | 0.51 | 0.50 | 0.80 | — |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | (24.00%) | (12.95%) | (31.39%) | (21.91%) | (4.26%) | — |
Free Cash Flow Yield |
— | — | — | (18.52%) | (12.82%) | (27.86%) | (20.69%) | (0.86%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.35 | 0.54 | 0.14 | 0.05 | 1.29 | 0.00 |
Operating CF per Share |
(28.23) | (17.95) | (3.57) | (2.12) | (2.22) | (2.16) | (1.48) | (0.04) | (0.95) |
Capex per Share |
(2.68) | (7.14) | (0.08) | (0.05) | (0.05) | (0.04) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(30.92) | (25.09) | (3.65) | (2.17) | (2.27) | (2.20) | (1.49) | (0.04) | (0.95) |
Cash per Share |
0.57 | 57.91 | 8.76 | 4.45 | 6.17 | 4.51 | 3.85 | 3.89 | 5.56 |
Shareholders Equity per Share |
1.86 | 60.46 | 7.89 | 3.75 | 5.98 | 4.42 | 3.84 | 3.92 | 5.51 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.86 | 60.46 | 7.89 | 3.75 | 5.98 | 4.42 | 3.84 | 3.92 | 5.51 |
Free Cash Flow |
(21.98) | (31.54) | (40.34) | (55.00) | (80.19) | (99.01) | (91.47) | (2.50) | (60.38) |
Working Capital |
(1.45) | 69.87 | 87.94 | 92.79 | 206.80 | 190.79 | 228.52 | 238.88 | 344.43 |
Capital Expenditures |
(1.91) | (8.98) | (0.85) | (1.34) | (1.71) | (1.96) | (0.51) | (0.28) | (0.31) |
Net Current Asset Value |
(1.68) | 64.32 | 76.80 | 85.11 | 202.54 | 179.78 | 219.70 | 232.24 | 340.20 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.15 | 0.09 | 0.31 | 0.18 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (802.66%) | (421.89%) | (1,732.43%) | (3,470.05%) | (12.16%) | 0.00% |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.24 | 0.13 | 0.22 | 0.28 | 0.34 | 0.35 | 0.42 | 0.41 | 0.49 |
Cash ROIC |
(1,331.17%) | (22.25%) | (26.48%) | (29.82%) | (19.98%) | (25.87%) | (20.40%) | (1.26%) | (8.97%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 6.68 | 6.21 | 3.28 | 7.32 | 60.77 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.27 | 0.27 | 0.31 | 1.32 | 3.08 | 1.93 | 0.38 | 1.32 | — |
Average Payables |
1.47 | 1.47 | 1.72 | 3.13 | 4.43 | 4.21 | 3.20 | 1.96 | 1.38 |
Average Assets |
45.06 | 45.06 | 98.11 | 120.01 | 182.29 | 230.84 | 242.19 | 259.21 | 313.50 |
Average Common Equity |
(48.47) | (48.47) | 11.74 | 91.17 | 153.36 | 205.24 | 217.07 | 239.11 | 296.02 |
Columns are period end dates